CRISPR based technologies and bio-products

12th Danish Conference on Biotechnology and Molecular Biology (DCB12)

Hosted by the Danish Biotechnological Society (DBS)

Genome editing and the utilization of CRISPR based technologies are expected to revolutionize the production of the next generation of bioproducts. DCB12 will focus on the latest developments in the use of CRISPR/Cas9 and other CRISPR based technologies in relation to the development and production of biopharmaceuticals, biochemicals, agricultural crops and translational applications.

✦ Program ✦

► The conference will include sessions on:
- Drug screening
- Production of bio-pharmaceuticals
- Therapeutics
- Plant cell factories and agro-science
- Mammalian and microbial cell factories
- Legal and regulatory aspects
- Tools and future directions

► Accepted speakers
- Alex Toftegaard Nielsen, The Technical University of Denmark, DK
- Birger Lindberg Møller, University of Copenhagen, DK
- Claudio Mussolino, University Medical Center Freiburg, D 
- Gorm Greisen, The Danish Council on Ethics, DK 
- Helene Faustrup Kildegaard, NNF Biosustainability Centre, The Technical University of Denmark, DK
- Jon Chesnut, Thermo Fisher Scientfic, USA 
- Leslie Mitchell, New York University, Langone Medical Center, USA
- Lorenz Mayer, AstraZeneca, UK 
- Mark Behlke, Integrated DNA Technologies, USA 
- Matthew H. Porteus, Stanford University, USA
- Pascale Daran-Lapujade, Delft University, NL
- Sofia Håkansson Buch, Novo Nordisk A/S, DK. 
- Philippe Horvath, DuPont-Danisco, F.
- Philip Webber, Dehns Patent & Trade Mark Attorneys, UK 
- TBA, Millipore Sigma, USA 


► More info and registration here: http://danishbiotechsociety.org/conferences-events/